Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor

This is the first report in which crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, reduced an atypical carcinoid tumor with ALK rearrangement. A 70-year-old man developed a tumor in the left lung and multiple metastases to the lung and brain. The pathology of transbronchial biopsied specim...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Intern Med
Päätekijät: Nakajima, Masayuki, Uchiyama, Naoki, Shigemasa, Rie, Matsumura, Takeshi, Matsuoka, Ryota, Nomura, Akihiro
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: The Japanese Society of Internal Medicine 2016
Aiheet:
Case Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5140865/
https://ncbi.nlm.nih.gov/pubmed/27803410
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia